

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAVXR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 04 Precision of EMBASE searching enhanced with new
chemical name field
NEWS 3 OCT 06 Increase your retrieval consistency with new formats or
for Taiwanese application numbers in CA/CAPLUS.
NEWS 4 OCT 21 CA/CAPLUS kind code changes for Chinese patents
increase consistency, save time
NEWS 5 OCT 22 New version of STN Viewer preserves custom
highlighting of terms when patent documents are
saved in .rtf format
NEWS 6 OCT 28 INPADOCDB/INPAFAMDB: Enhancements to the US national
patent classification.
NEWS 7 NOV 03 New format for Korean patent application numbers in
CA/CAPLUS increases consistency, saves time.
NEWS 8 NOV 04 Selected STN databases scheduled for removal on
December 31, 2010
NEWS 9 NOV 18 PROUSDDR and SYNTHLINE Scheduled for Removal
December 31, 2010 by Request of Prous Science
NEWS 10 NOV 22 Higher System Limits Increase the Power of STN
Substance-Based Searching
NEWS 11 NOV 24 Search an additional 46,850 records with MEDLINE
backfile extension to 1946
NEWS 12 DEC 14 New PNK Field Allows More Precise Crossover among STN
Patent Databases
NEWS 13 DEC 18 ReaxysFile available on STN
NEWS 14 DEC 21 CAS Learning Solutions -- a new online training experience
NEWS 15 DEC 22 Value-Added Indexing Improves Access to World Traditional
Medicine Patents in CAPLUS
NEWS 16 JAN 24 The new and enhanced DPCI file on STN has been released
NEWS 17 JAN 26 Improved Timeliness of CAS Indexing Adds Value to
USPATFULL and USPAT2 Chemistry Patents
NEWS 18 JAN 26 Updated MeSH vocabulary, new structured abstracts, and
other enhancements improve searching in STN reload of
MEDLINE
NEWS 19 JAN 28 CABA will be updated weekly
NEWS 20 FEB 23 PCTFULL file on STN completely reloaded
NEWS 21 FEB 23 STN AnaVist Test Projects Now Available for
Qualified Customers
NEWS 22 FEB 25 LPCI will be replaced by LDPCI
NEWS 23 MAR 07 Pricing for SELECTing Patent, Application, and Priority
Numbers in the USPAT and IFI Database Families is Now
Consistent with Similar Patent Databases on STN

NEWS EXPRESS 17 DECEMBER 2010 CURRENT WINDOWS VERSION IS V8.4.2 .1,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2011 HIGHEST RN 1278651-19-6
DICTIONARY FILE UPDATES: 11 APR 2011 HIGHEST RN 1278651-19-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Documents and Settings\vrodriguezgarci\My Documents\e-Red Folder\10598846\L1.str



```

chain nodes :
22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24
25 26 27 28
chain bonds :
11-16 19-22 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26
26-27 27-28
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 16-17 16-21 17-18 18-19 19-20 19-22 20-21
exact bonds :
11-16 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15 23-24 23-28
24-25 25-26 26-27 27-28

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

```

=> s sam sss l1
SAMPLE SEARCH INITIATED 08:45:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 284 TO ITERATE

100.0% PROCESSED 284 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4669 TO 6691
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> file zcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.04 2.27

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2011 VOL 154 ISS 16
FILE LAST UPDATED: 12 Apr 2011 (20110412/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

ZCPlus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s sam sss l1
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 08:46:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 284 TO ITERATE

100.0% PROCESSED 284 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4669 TO 6691
PROJECTED ANSWERS: 1 TO 80

L3 1 SEA SSS SAM L1

L4 0 L3

=> file registry
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.08 2.94

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2011 HIGHEST RN 1278651-19-6
DICTIONARY FILE UPDATES: 11 APR 2011 HIGHEST RN 1278651-19-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s sam sss l1
SAMPLE SEARCH INITIATED 08:46:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 284 TO ITERATE


100.0% PROCESSED 284 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4669 TO 6691
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L1

=> d sca

L5 1 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
 IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[1-(3-pyridinyl)ethyl]-4-piperidinylidene]-
 MF C26 H26 Cl N3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Documents and Settings\vrodriguezgarcia\My Documents\e-Red
 Folder\10598846\L6.str



```

chain nodes :
22 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24
25 26 27 28
chain bonds :
11-16 19-22 22-23 22-29 22-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26
26-27 27-28
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 16-17 16-21 17-18 18-19 19-20 19-22 20-21
exact bonds :
11-16 22-23 22-29 22-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15 23-24 23-28
24-25 25-26 26-27 27-28

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS

```

L6 STRUCTURE UPLOADED

=> s sam sss l6

SAMPLE SEARCH INITIATED 08:48:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 284 TO ITERATE

100.0% PROCESSED 284 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4669 TO 6691

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s full sss l6

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 08:50:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5877 TO ITERATE

100.0% PROCESSED 5877 ITERATIONS

31 ANSWERS

SEARCH TIME: 00.00.01

L8 31 SEA SSS FUL L6

=> file zcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

200.43

203.37

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2011 VOL 154 ISS 16

FILE LAST UPDATED: 12 Apr 2011 (20110412/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8
L9 124 L8

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.84	205.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2011 HIGHEST RN 1279198-64-9
DICTIONARY FILE UPDATES: 12 APR 2011 HIGHEST RN 1279198-64-9

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d sca l8

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]-
MF C26 H24 Cl N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, nitrate (1:?)
MF C26 H26 Cl N3 . x H N O3

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
MF C26 H26 Cl N3 . x C4 H6 O6

CM 1



CM 2

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN

IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(1-oxido-3-pyridinyl)methyl]-4-
piperidinylidene]-


MF C25 H24 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, hydrochloride (1:3)
MF C26 H26 Cl N3 . 3 Cl H



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl)methyl]-,
methyl ester
MF C27 H26 Cl N3 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
 IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-, sulfate (1:?)
 MF C26 H26 Cl N3 . x H2 O4 S

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
 IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-
 dihydro-
 MF C25 H23 Br Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 31 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
 IN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-
 MF C26 H26 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file zcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.02

206.23

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2011 VOL 154 ISS 16

FILE LAST UPDATED: 12 Apr 2011 (20110412/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

ZCaplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

L1 FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
 L2 STRUCTURE UPLOADED
 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
 S L1

L3 FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
 1 S L1 SSS SAM

L4 FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
 0 S L3 SSS SAM

L5 FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
 L6 1 S SAM SSS L1
 L7 STRUCTURE UPLOADED
 L8 0 S SAM SSS L6
 31 S FULL SSS L6

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
 L9 124 S L8

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011

=> s l9 and (crystal or crystalline)
 1632422 CRYSTAL
 765969 CRYSTALS
 1962260 CRYSTAL
 (CRYSTAL OR CRYSTALS)
 98110 CRYSTALLINE
 343 CRYSTALLINES
 98423 CRYSTALLINE
 (CRYSTALLINE OR CRYSTALLINES)
 419323 CRYST
 1805 CRYSTS
 420595 CRYST
 (CRYST OR CRYSTS)
 454916 CRYSTALLINE
 (CRYSTALLINE OR CRYST)

L10 4 L9 AND (CRYSTAL OR CRYSTALLINE)

=> d ibib abs hitstr 1-4
 THE ESTIMATED COST FOR THIS REQUEST IS 23.84 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L10 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 2008:1521725 ZCAPLUS

DOCUMENT NUMBER: 150:84138

TITLE: Quality control method of rupatadine fumarate

INVENTOR(S): Peng, Hongwei; Yang, Wei; Zhao, Bin; Zeng, Yujian;
 Zhao, Haifeng; Dong, Zhaoyong

PATENT ASSIGNEE(S): Guangdong Kanghong Pharmaceutical Co. , Ltd., Peop.
 Rep. China


SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 39pp.
 CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 101324551	A	20081217	CN 2007-10028542	20070612
PRIORITY APPLN. INFO.:				CN 2007-10028542	20070612
AB	Rupatadine fumarate is a kind of anti-allergic medicine with antihistamine effect and antagonistic activity to platelet activating factor, and can be used for treating allergic rhinitis. The title quality control method of rupertadine fumarate comprises of: (1) part of or whole character inspection of appearance, hygroscopicity, solubility and m.p., (2) functional group identification via high performance liquid chromatog. and/or IR spectroscopic anal., (3) part of or whole detection of chlorides, relative substances, organic residues, loss on drying, combustion residue, and heavy metals, and (4) rupatadine fumarate content measurement via high performance chromatog. and/or nonaq. titration The quality control method has high specificity, stability and accuracy, and is simple in operation.				
IT	158876-82-5, Rupatadine RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (quality control method of rupatadine fumarate)				
RN	158876-82-5 ZCAPLUS				
CN	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)				



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L10 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:927512 ZCAPLUS
DOCUMENT NUMBER: 150:523475
TITLE: Polymorphs of rupatadine fumarate
INVENTOR(S): Darji, Dharmendra Arvindbhai; Patel, Mahesh
Shankarbhaj; Kumar, Rajiv; Dwivedi, Shriprakash Dhar
PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
SOURCE: Indian Pat. Appl., 30pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	IN 2006MU01471	A	20080725	IN 2006-MU1471	20060915
PRIORITY APPLN. INFO.:					
AB	A crystalline form of rupatadine fumarate is characterized by x-ray powder diffraction.				
IT	182349-12-8P				
	RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(polymorphs of rupatadine fumarate)				
RN	182349-12-8	ZCAPLUS			
CN	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)				
CM	1				
CRN	158876-82-5				
CMF	C26 H26 Cl N3				




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




IT 158876-82-5

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(polymorphs of rupatadine fumarate)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L10 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:5893 ZCAPLUS

DOCUMENT NUMBER: 146:128584

TITLE: New disintegrant tablet formulation of rupatadine

INVENTOR(S): Liao, Juan; Chen, Yang

PATENT ASSIGNEE(S): Beijing D-Venturepharm.T. Corp., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1883480	A	20061227	CN 2005-10077340	20050622
PRIORITY APPLN. INFO.:			CN 2005-10077340	20050622

AB The invention provides a new disintegrant tablet formulation of rupatadine. The composition is composed of rupatadine, excipient, bulking agent, diluting agent, binding agent, disintegrant, lubricant, wetting agent, and sweetening agent. The formulation may be tablet, dispersing tablet, orally disintegrating tablet, and/or capsule. The preparation of tablet comprises, for example, (1) sieving rupatadine fumarate with 100 mesh sieve, magnesium stearate with 60 mesh sieve, other materials with 80 mesh sieve; (2) mixing main drug with lactose, then with other adjuvants; (3) prilling with 10% starch syrup, drying at 50 °C; (4) mixing with magnesium stearate, and pressing to obtain the product.


IT 158876-82-5, Rupatadine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new disintegrant tablet formulation of rupatadine)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L10 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:1030442 ZCAPLUS

DOCUMENT NUMBER: 145:397370

TITLE: Process for the preparation of a polymorphic crystalline form of rupatadine free base

INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari; Subash Chander Reddy, Kesireddy

PATENT ASSIGNEE(S): Hetero Drugs Limited, India

SOURCE: PCT Int. Appl., 15pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103688	A1	20061005	WO 2005-IN97	20050401
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1863788	A1	20071212	EP 2005-742906	20050401
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2006CN01189	A	20070720	IN 2006-CN1189	20060406
US 20090197907	A1	20090806	US 2009-598846	20090324
PRIORITY APPLN. INFO.:			WO 2005-IN97	W 20050401

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:397370

AB A novel crystalline form of rupatadine free base, a process for its preparation, and a pharmaceutical composition containing it are described. Rupatadine

is suspended in n-hexane, n-heptane, cyclohexane, di-Et ether, or

diisopropyl ether, stirred for at least 1 h, the solid filtered and dried to give crystalline rupatadine form B.

IT 182349-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(in a process for the preparation of a polymorphic crystalline form of rupatadine free base)


RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




IT 158876-82-5P, Rupatadine

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(process for the preparation of a polymorphic crystalline form of rupatadine free base)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011

L1 STRUCTURE UPLOADED

L2 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011

S L1

FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011

L3 1 S L1 SSS SAM

FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011

L4 0 S L3 SSS SAM

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011

L5 1 S SAM SSS L1

L6 STRUCTURE UPLOADED

L7 0 S SAM SSS L6

L8 31 S FULL SSS L6

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011

L9 124 S L8

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011

L10 4 S L9 AND (CRYSTAL OR CRYSTALLINE)

=> s l9 and polymorph

11005 POLYMORPH

12989 POLYMORPHS

19151 POLYMORPH

(POLYMORPH OR POLYMORPHS)

L11 1 L9 AND POLYMORPH

=> s l9 and polymorph?

L12 306775 POLYMORPH?
5 L9 AND POLYMORPH?

=> s l12 not l10
L13 3 L12 NOT L10

=> s l9 (L) polymorph?
306775 POLYMORPH?
L14 2 L9 (L) POLYMORPH?

=> s l9 (W) polymorph?
306775 POLYMORPH?
L15 1 L9 (W) POLYMORPH?

=> s l14 not l13
L16 2 L14 NOT L13

=> s l14 and l13
L17 0 L14 AND L13

=> s l14 not l10
L18 0 L14 NOT L10

=> d ibib abs hitstr l13 1-3
THE ESTIMATED COST FOR THIS REQUEST IS 17.88 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13 ANSWER 1 OF 3 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2010:785907 ZCAPLUS
DOCUMENT NUMBER: 153:108912
TITLE: Oxepine modulators of h1 receptors and/or inhibitors
of mast cell degranulation
INVENTOR(S): Gant, Thomas G.; Shahbaz, Manouchehr M.
PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 51pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100160272	A1	20100624	US 2009-641397	20091218
WO 2010080577	A2	20100715	WO 2009-US68654	20091218
WO 2010080577	A3	20101028		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, AE, EP, OA

PRIORITY APPLN. INFO.: US 2008-138568P P 20081218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 153:108912

AB The present invention relates to new oxepine modulators of H1 receptors


and/or inhibitors of mast cell degranulation, pharmaceutical comps. thereof, and methods of use thereof.

IT 158876-82-5, Rupatadine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (deuterium-enriched oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L13 ANSWER 2 OF 3 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:596607 ZCAPLUS

DOCUMENT NUMBER: 152:548261

TITLE: Preparation of deuterated steroid modulators of glucocorticoid receptor

INVENTOR(S): Gant, Thomas G.; Shahbaz, Manouchehr

PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010054158	A2	20100514	WO 2009-US63501	20091106
WO 2010054158	A3	20100819		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20100120733	A1	20100513	US 2009-613628	20091106

PRIORITY APPLN. INFO.:

US 2008-112268P


P 20081107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):

MARPAT 152:548261

GI



AB The present invention relates to new steroid modulators I [R1 - R31 and R35 - R41 are independently selected from the group consisting of H or deuterium; R32 and R33 are independently selected from the group consisting of Me, CH₂D, CHD₂, CD₃; R34 = OC(:O)CR₄₁(CR₃₅R₃₆R₃₇)(CR₃₈R₃₉R₄₀); and at least one of R1 - R33 and R35 - R41 is deuterium or contains deuterium], or a pharmaceutically acceptable salt thereof, of glucocorticoid receptor activity, pharmaceutical compns. thereof, and methods of use thereof. The physiol. of I was studied using: an in vitro liver microsomal stability assay; an in vitro metabolism assay with human cytochrome P 450 enzymes; and, an assay with monoamine oxidase inhibition and oxidative turnover.


IT 158876-82-5, Rupatadine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination chemotherapy antihistamine; preparation of deuterated steroid modulators of glucocorticoid receptor)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



L13 ANSWER 3 OF 3 ZCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2008:42786 ZCAPLUS
 DOCUMENT NUMBER: 148:119180
 TITLE: Genetic markers in tachykinin NK1 receptor gene TACR1
 that correlate with asthma disorders
 INVENTOR(S): Halapi, Eva; Hakonarson, Hakon
 PATENT ASSIGNEE(S): Decode Genetics Enh., USA
 SOURCE: PCT Int. Appl., 133pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006105	A2	20080110	WO 2007-US73066	20070709
WO 2008006105	A9	20080403		
WO 2008006105	A3	20080814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2006-819198P P 20060707
 OTHER SOURCE(S): MARPAT 148:119180

AB Polymorphisms in the exon 2 LD block of gene TACR1 encoding tachykinin receptor 1 are shown by association anal. to be a susceptibility gene for asthma. Methods of diagnosis of susceptibility to asthma, of decreased susceptibility to asthma and protection against asthma, are described, as are methods of treatment for asthma.

IT 158876-82-5, Rupatadine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (genetic markers in tachykinin NK1 receptor gene TACR1 that correlate with asthma disorders)

RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
 STRUCTURE UPLOADED

L1
 L2 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
 S L1

FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
 L3 1 S L1 SSS SAM

FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
 L4 0 S L3 SSS SAM

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011
 L5 1 S SAM SSS L1

L6 STRUCTURE UPLOADED

L7 0 S SAM SSS L6

L8 31 S FULL SSS L6

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
 L9 124 S L8

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011

L10 4 S L9 AND (CRYSTAL OR CRYSTALLINE)

L11 1 S L9 AND POLYMORPH

L12 5 S L9 AND POLYMORPH?

L13 3 S L12 NOT L10

L14 2 S L9 (L) POLYMORPH?

L15 1 S L9 (W) POLYMORPH?

L16 2 S L14 NOT L13

L17 0 S L14 AND L13
L18 0 S L14 NOT L10

=> s l9/prep

FIELD CODES CANNOT BE CHANGED HERE

You may have tried to apply a field code to a term that already has a field code. You can only add a field code to a term that has no field code appended to it.

=> s l8/prep

124 L8
5204403 PREP/RL

L19 21 L8/PREP
(L8 (L) PREP/RL)

=> s l19 not l10

L20 19 L19 NOT L10

=> s l20 not l13

L21 19 L20 NOT L13

=> d ibib abs hitstr 17-19

THE ESTIMATED COST FOR THIS REQUEST IS 17.88 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L21 ANSWER 17 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1996:635179 ZCAPLUS

DOCUMENT NUMBER: 125:275664

ORIGINAL REFERENCE NO.: 125:51553a,51556a

TITLE: 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine fumarate and its preparation and use as a PAF antagonist and antihistaminic

INVENTOR(S): Carceller, Elena; Recasens, Nuria; Almansa, Carmen; Bartroli, Javier; Merlos, Manel; Giral, Marta
PATENT ASSIGNEE(S): J. Uriach & Cia. S.A., Spain

SOURCE: Span., 11 pp.

CODEN: SPXXAD


DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
ES 2087818	A1	19960716	ES 1993-2460	19931124
ES 2087818	B1	19970316		
NO 9404487	A	19950526	NO 1994-4487	19941123
PRIORITY APPLN. INFO.:			ES 1993-2460	A 19931124
GI				



I

AB The title salt I-fumarate is prepared for use as an antagonist of PAF (platelet activating factor) and an antihistaminic (no data). I-fumarate has improved hygroscopicity and light stability in comparison to I.3HCl or the free base I. For example, I was prepared from loratadine by a sequence of: hydrolytic removal of the N-ethoxycarbonyl group (84%), N-acylation with 5-methylnicotinic acid using DCC and HOBT (65%), and chlorination/reduction of the amide using POCl₃ followed by NaBH₄ (72%). Treatment of I with fumaric acid in EtOH gave 70% I-fumarate. When exposed to 98% humidity for 24 h, H₂O contents were 5.7% for I, and 28.3% for I.3HCl, but only 0.29% for I-fumarate. Similarly, irradiation at 150 klx for 1 h reduced purities to 92.7% for I, to 74% for I.3HCl, but only to 99.2% for I-fumarate.

IT 158876-82-5P


RL: IMF (Industrial manufacture); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(comparison compound; preparation of benzocycloheptapyridine derivative fumarate

salt as PAF antagonist and antihistaminic with improved properties)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 156611-76-6P


RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(comparison compound; preparation of benzocycloheptapyridine derivative fumarate

salt as PAF antagonist and antihistaminic with improved properties)

RN 156611-76-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

IT 182349-12-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzocycloheptapyridine derivative fumarate salt as PAF antagonist and antihistaminic with improved properties)


RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L21 ANSWER 18 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:680552 ZCAPLUS

DOCUMENT NUMBER: 121:280552

ORIGINAL REFERENCE NO.: 121:51219a, 51222a

TITLE: Process for preparation of
8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-
piperidylidene]-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine and analogs as
antihistaminics and PAF antagonists

INVENTOR(S): Carceller, Elena; Recasens, Nuria; Almansa, Carmen;
Almansa, Javier; Merlos, Manuel; Giral, Marta;
Garcia-Rafanell, Julian; Forn, Javier
PATENT ASSIGNEE(S): J. Uriach y Cia S.A., Spain

SOURCE: Span., 18 pp.
CODEN: SPXXAD


DOCUMENT TYPE: Patent
LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2042421	A1	19931201	ES 1992-1054	19920522
ES 2042421	B1	19940801		
CA 2096318	A1	19931123	CA 1993-2096318	19930514
CA 2096318	C	19980623		
US 5407941	A	19950418	US 1993-61720	19930517
EP 577957	A1	19940112	EP 1993-108177	19930519

EP 577957 B1 19950712
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 JP 06087856 A 19940329 JP 1993-117427 19930519
 JP 2730612 B2 19980325
 AT 124939 T 19950715 AT 1993-108177 19930519
 ES 2076817 T3 19951101 ES 1993-108177 19930519
 KR 156518 B1 19981116 KR 1993-8812 19930521
 US 5476856 A 19951219 US 1995-391702 19950221
 PRIORITY APPLN. INFO.: ES 1992-1054 A 19920522
 US 1993-61720 A1 19930517
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 121:280552
 GI



I




II

AB Nine title compds. I [R = H, halo, C1-4 alkyl, C1-4 alkoxy] and a salt were prepared and tested. For example, the drug loratadine [II; R1 = CO2Et] was treated with Me3SiI in CHCl3 at 55-60° under Ar to give 77% II (R1 = H). N-alkylation of this by 3-methyl-5-(bromomethyl)pyridine [prepared in situ by NBS bromination of 3,5-lutidine] in CCl4 in the presence of DMAP gave 40% I (R = 5-Me) (III), the most active compound. In a test for H1-antihistaminic activity, III was 20 times as potent as the known unsubstituted 4-pyridyl analog, and 25-70 times as potent as loratadine and 2 other carbonyl-containing analogs. In tests of I and the standard compds. for antagonism of platelet activating factor (PAF), only II showed potent activity, being at least 10-fold more active than the other compds.

IT 158876-82-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of [(pyridylmethyl)piperidylidene]benzocycloheptapyridine derivs. as antihistaminics and PAF antagonists)

RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)




IT 156522-82-6P 156522-86-0P 156522-87-1P
 156522-88-2P 156522-89-3P 156522-94-0P
 156522-95-1P 156611-76-6P 158876-81-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of [(pyridylmethyl)piperidylidene]benzocycloheptapyridine derivs. as antihistaminics and PAF antagonists)


RN 156522-82-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-(3-pyridinylmethyl)-4-piperidinylidene]- (CA INDEX NAME)




RN 156522-86-0 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-dihydro- (CA INDEX NAME)




RN 156522-87-1 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-11-[1-[(6-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-
dihydro- (CA INDEX NAME)




RN 156522-88-2 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-11-[1-[(2-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-
dihydro- (CA INDEX NAME)




RN 156522-89-3 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(6-methoxy-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156522-94-0 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156522-95-1 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(4-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156611-76-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 158876-81-4 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
 RECORD (24 CITINGS)

L21 ANSWER 19 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:524597 ZCAPLUS


DOCUMENT NUMBER: 121:124597

ORIGINAL REFERENCE NO.: 121:22229a, 22232a

TITLE: [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine
 Derivatives as Dual Antagonists of PAF and Histamine
 AUTHOR(S): Carceller, Elena; Merlos, Manuel; Giral, Marta; Balsa,
 Dolores; Almansa, Carmen; Bartroli, Javier;
 Garcia-Rafanell, Julian; Forn, Javier


CORPORATE SOURCE: Research Center, J. Uriach Cia.S.A., Barcelona, 08026,

SOURCE: Spain
 Journal of Medicinal Chemistry (1994), 37(17),
 2697-703
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:124597
 AB A series of [(3-pyridylalkyl)piperidylidene]- and
 (nicotinoylpiperidylidene)benzocycloheptapyridine derivs. were prepared and
 evaluated for PAF antagonist and H1 antihistamine activity. PAF
 antagonist activity was investigated by the in vitro PAF-induced platelet
 aggregation assay (PPA) and the in vivo PAF-induced hypotension test in
 rats (PH) and mortality test in mice (PM). For the evaluation of H1
 antihistamine activity, the in vitro histamine-induced contraction of the
 guinea-pig ileum assay (HC) and the in vivo histamine-induced hypotension
 test (HH) in normotensive rats were used. The potential antiallergic
 activity of the compds. was evaluated using the active anaphylactic shock
 test in mice. These compds. are structurally related to loratadine (1)
 and were generated by replacement of the ethoxycarbonyl group of 1 with
 substituted 3-pyridylmethyl and nicotinoyl moieties. Both anti-PAF and H1
 antihistamine activities have shown a high dependence on the exact nature
 and position of the substituent in the pyridine ring. The optimum
 structure, incorporating a (5-methyl-3-pyridyl)methyl radical, displayed
 an unique dual activity inhibiting both PAF-induced effects (PPA, IC50 =
 3.7 µM; PH, ID50 = 0.44 mg/kg i.v.; PM, ID50 = 1.9 mg/kg po) and
 histamine-induced effects (HC, IC50 = 3.9 nM; HH, ID50 = 1.4 mg/kg i.v.).
 Furthermore, this compound was highly active in the passive cutaneous
 anaphylactic shock in rats (ID50 = 1.2 mg/kg po) and strongly protected
 mice and rats from mortality induced by endotoxin (ID50 = 1.2 and 0.5
 mg/kg i.v., resp.). It showed itself to be devoid of CNS depressant
 effects, neither modifying spontaneous motor activity nor prolonging
 barbiturate-sleeping time in mice at a dose of 100 mg/kg po, and is now
 under development.
 IT 156522-82-6P 156522-83-7P 156522-86-0P
 156522-87-1P 156522-88-2P 156522-89-3P
 156522-90-6P 156522-91-7P 156522-92-8P
 156522-93-9P 156522-94-0P 156522-95-1P
 156611-76-6P, UR 12592
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antihistaminic and PAF-antagonistic activity of, structure
 in relation to)
 RN 156522-82-6 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-(3-pyridinylmethyl)-4-piperidinylidene]- (CA
 INDEX NAME)




RN 156522-83-7 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(1-oxido-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156522-86-0 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
11-[1-[(5-bromo-3-pyridinyl)methyl]-4-piperidinylidene]-8-chloro-6,11-
dihydro- (CA INDEX NAME)




RN 156522-87-1 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-11-[1-[(6-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-
dihydro- (CA INDEX NAME)




RN 156522-88-2 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-11-[1-[(2-chloro-3-pyridinyl)methyl]-4-piperidinylidene]-6,11-
dihydro- (CA INDEX NAME)




RN 156522-89-3 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(6-methoxy-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156522-90-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(2-methoxy-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)



RN 156522-91-7 ZCAPLUS


CN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 156522-92-8 ZCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 156522-93-9 ZCAPLUS


CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(6-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 156522-94-0 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(2-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)




RN 156522-95-1 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(4-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)



RN 156611-76-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

=> d ibib abs hitstr 6-16

THE ESTIMATED COST FOR THIS REQUEST IS 65.56 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L21 ANSWER 6 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:848861 ZCAPLUS

DOCUMENT NUMBER: 150:398361

TITLE: Process for preparation of highly pure Rupatadine and intermediates

INVENTOR(S): Patel, Mahesh Shankarbhai; Kumar, Rajiv; Dwivedi, Shriprakash Dhar

PATENT ASSIGNEE(S): Cadila Healthcare Limited, India

SOURCE: Indian Pat. Appl., 28pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00864	A	20080704	IN 2006-MU864	20060605
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			IN 2006-MU864	20060605


CASREACT 150:398361; MARPAT 150:398361

AB This invention provides a process for the preparation of ACH2OSO2R [wherein A = 5-methyl-3-pyridyl; R = Me, Et, Pr, iso-Pr, Bu, iso-Bu, benzyl, tolyl, etc.] as intermediates for synthesizing highly pure Rupatadine. For example, Me 5-methylnicotinate was reduced with sodium borohydride to obtain 5-methyl-3-pyridylmethanol, followed by reaction with 4-methylbenzenesulfonyl chloride to give 5-methyl-3-pyridinemethanol tosylate. The previous obtained sulfonate was reacted with Desloratadine in acetone at 30-35 °C to give Rupatadine.

IT 158876-82-5P, Rupatadine

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of highly pure Rupatadine and intermediates)
 RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)




IT 182349-12-8P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (preparation of highly pure Rupatadine and intermediates)

RN 182349-12-8 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5
 CMF C26 H26 Cl N3



CM 2


CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




L21 ANSWER 7 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:1468011 ZCAPLUS
DOCUMENT NUMBER: 148:262449
TITLE: Expedient synthesis of rupatadine
AUTHOR(S): Agarwal, Rajendra; Bhirud, Shekhar Bhaskar; Bijukumar, Gopinathpillai; Khude, Gopal Dnyandeve
CORPORATE SOURCE: Research and Development Centre, Chemical Process Research and Development, Macleods Pharmaceuticals Ltd., Mumbai, India
SOURCE: Synthetic Communications (2008), 38(1), 122-127
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:262449
AB Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), was synthesized in 91% overall yield.
IT 158876-82-5P, Rupatadine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of rupatadine starting from methylnicotinic acid)
RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)




IT 182349-12-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rupatadine starting from methylnicotinic acid)
RN 182349-12-8 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1
CRN 158876-82-5
CMF C26 H26 Cl N3



CM 2
CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1460686 ZCAPLUS

DOCUMENT NUMBER: 149:513665

TITLE: Synthesis of 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (rupatadine)
Zhang, Wanjin; Luo, Yan; Zhang, Yanmei
CORPORATE SOURCE: Dept. of Medicinal Chemistry, Guangdong Pharmaceutical College, Guangzhou, Guangdong Province, 510224, Peop. Rep. China

SOURCE: Zhongguo Yiyao Gongye Zazhi (2006), 37(7), 433-435
CODEN: ZYGZEA; ISSN: 1001-8255

PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu


DOCUMENT TYPE: Journal

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 149:513665

AB Rupatadine was synthesized from 2-cyano-3-methylpyridine by a synthetic sequence involving a Ritter reaction, alkylation, cyanidation, hydrolysis and cyclization to give 8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one, which was subjected to Grignard reaction and then dehydration with an overall yield of 18.7%.

IT 158876-82-5P, Rupatadine
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of rupatadine via synthetic sequence involving Ritter reaction,
 alkylation, cyanation, hydrolysis, cyclization, formation of
 chlorodihydrobenzo[5,6]cyclohepta[1,2-b]pyridinone, Grignard reaction
 and dehydration)
 RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L21 ANSWER 9 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:655783 ZCAPLUS
 DOCUMENT NUMBER: 148:426751
 TITLE: Process for the synthesis of rupatadine
 INVENTOR(S): Rajendra, Agarwal; Gopinathan, Pillai Bijukumar;
 Dnyande, Khude Gopal; Bhaskar, Bhirud Shekhar
 PATENT ASSIGNEE(S): MacLeods Pharmaceuticals Limited, India
 SOURCE: Indian Pat. Appl., 14pp.
 CODEN: INXXBQ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU02102	A	20070608	IN 2006-MU2102	20061222
PRIORITY APPLN. INFO.:			IN 2006-MU2102	20061222


OTHER SOURCE(S): CASREACT 148:426751
 AB An improved and industrially feasible process for the preparation of
 8-chloro-6,11-dihydro-11-[1-[(methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2b]pyridine (rupatadine).
 Rupatadine was prepared by esterification of 5-methylnicotinic acid; the
 resulting 5-methylnicotinate underwent reduction to give
 5-methylpyridine-3-methanol, which underwent chlorination to give the
 corresponding chloromethylpyridine, which underwent condensation with
 desloratadine to give rupatadine, which was reacted with fumaric acid to
 give rupatadine fumarate.

IT 158876-82-5P, Rupatadine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(process for the synthesis of rupatadine)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]- (CA INDEX NAME)



IT 182349-12-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(process for the synthesis of rupatadine)


RN 182349-12-8 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



L21 ANSWER 10 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1236016 ZCAPLUS
DOCUMENT NUMBER: 146:45400
TITLE: Method for preparation of Rupatadine and its salt
INVENTOR(S): Qu, Feng; Wang, Yusheng
PATENT ASSIGNEE(S): Beijing Dezhong-Venture Pharmaceutical Technology Co.,
Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 6pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1865259	A	20061122	CN 2005-10070952	20050519
CN 1865259	B	20100929		

PRIORITY APPLN. INFO.: CN 2005-10070952 20050519
OTHER SOURCE(S): CASREACT 146:45400
GI




I

AB In this invention, Rupatadine is prepared by the reduction of I amide carbonyl group with Red-Al in THF, toluene, or DMF. Rupatadine can be obtained by reducing the amido bonds in the mols. of the compound or its salt in formula II in the presence of Red-Al.

IT 158876-82-5P, Rupatadine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of Rupatadine via the reduction of amide carbonyl group with Red-Al)

RN 158876-82-5 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L21 ANSWER 11 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on SIN

ACCESSION NUMBER: 2006:1147779 ZCAPLUS

DOCUMENT NUMBER: 145:471404

TITLE: Process for the preparation of rupatadine by

PTC-catalyzed N-alkylation of desloratadine

INVENTOR(S): Khamar, Bakulesh Mafatlal; Modi, Indravadan Ambalal;

Chandrakant, Shukla Manish; Kashyapbhai, Parikh

Krunal; Prabhakar, Dange Suryabhan; Ravi, Ponniah;

Jagdish, Desai Sanjay; Raman, J. Venkat

PATENT ASSIGNEE(S): Mafatlal, Khamar, Bakulesh, India; Ambalal, Modi,

Indravadan; Chandrakant, Shukla, Manish; Kashyapbhai,

Parikh, Krunal; Prabhakar, Dange, Suryabhan; Jagdish,

Desai, Sanjay; Raman, J., Venkat

SOURCE: PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114676	A2	20061102	WO 2006-IB964	20060422
WO 2006114676	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
IN 2005MU00516	A	20090626	IN 2005-MU516	20050427
ES 2311426	A1	20090201	ES 2007-50036	20060422
ES 2311426	B1	20091222		

PRIORITY APPLN. INFO.:

IN 2005-MU516

A 20050427

OTHER SOURCE(S):

CASREACT 145:471404

AB A process for the preparation of rupatadine, a potent orally active dual antagonist of platelet-activated factor and histamine, which comprises N-alkylating desloratadine with 3-(bromomethyl)-5-methylpyridine (I) or analogs in biphasic solvent systems, is disclosed. For instance, a mixture of desloratadine, dichloromethane, tetrabutylammonium bromide and NaOH aqueous solution is cooled to 0-5°C. After a mixture of I·HCl in dichloromethane was added, the whole was stirred at 0-5°C for 1 h and then at rt for 12 h to give rupatadine in 67.66% yield. A solution of this product in acetone was stirred with a solution of fumaric acid in methanol to afford rupatadine fumarate.


IT 158876-82-5P, Rupatadine

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of rupatadine via PTC-catalyzed N-alkylation of desloratadine in biphasic solvent systems)

RN 158876-82-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



IT 913746-24-4P 913746-25-5P 913746-26-6P

913746-27-7P 913746-28-8P 913746-29-9P

913746-30-2P 913746-31-3P 913746-32-4P


913746-33-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of rupatadine via PTC-catalyzed N-alkylation of desloratadine in biphasic solvent systems)


RN 913746-24-4 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 913746-25-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-, hydrobromide (1:?) (CA INDEX NAME)




● x HBr

RN 913746-26-6 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5
 CMF C26 H26 Cl N3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 913746-27-7 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3




CM 2
CRN 75-75-2
CMF C H4 O3 S




RN 913746-28-8 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1
CRN 158876-82-5
CMF C26 H26 Cl N3




CM 2
CRN 98-11-3
CMF C6 H6 O3 S




RN 913746-29-9 ZCAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX
NAME)

CRN 158876-82-5
CMF C26 H26 C1 N3




CRN 77-92-9
CMF C6 H8 O7



RN	913746-30-2	ZCAPLUS
CN	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4- piperidinylidene]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)	

CRN 158876-82-5
CMF C26 H26 C1 N3




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 913746-31-3 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 913746-32-4 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 913746-33-5 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
piperidinylidene]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 12 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:620660 ZCAPLUS

DOCUMENT NUMBER: 146:142463


TITLE: Improved synthesis of 5-methylpyridine-3-carboxylic

acid, the intermediate of rupatadine
 AUTHOR(S): Wang, Zhen-yu; Zhu, Xiong; Wang, Er-hua
 CORPORATE SOURCE: Medicinal and Chemical Institute, China Pharmaceutical
 University, Nanjing, 210009, Peop. Rep. China
 SOURCE: Yaoxue Jinzhan (2005), 29(1), 31-33
 CODEN: YJAIBE; ISSN: 1001-5094
 PUBLISHER: Yaoxue Jinzhan Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 OTHER SOURCE(S): CASREACT 146:142463

AB Objective: To improve the synthesis of 5-methylpyridine-3-carboxylic acid.
 Methods: 5-methylpyridine-3-carboxylic acid, the intermediate of
 Rupatadine, was synthesized from 3,5-lutidine by the reaction of oxidation
 with KMnO₄. The reaction conditions were optimized with the orthogonal
 matrix. Results: The suitable conditions were obtained, and the yield was
 51%.

IT 158876-82-5P, Rupatadine
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of 5-methylpyridine-3-carboxylic acid as intermediate of
 rupatadine)

RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)




L21 ANSWER 13 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:515027 ZCAPLUS
 DOCUMENT NUMBER: 144:369863
 TITLE: Synthesis of Rupatadine
 AUTHOR(S): Xin, Shiu-bo; Wu, Fan-hong
 CORPORATE SOURCE: College of Chemistry and Pharmaceutics, East China
 University of Science and Technology, Shanghai,
 200237, Peop. Rep. China
 SOURCE: Zhongguo Xinyao Zazhi (2005), 14(4), 451-452
 CODEN: ZXZHA6; ISSN: 1003-3734
 PUBLISHER: Zhongguo Xinyao Zazhishe
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

AB Rupatadine was prepared from Loratadine via hydrolysis and alkylation to
 provide the product with overall yield 32.4%.

IT 158876-82-5P, Rupatadine
 RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of Rupatadine)
 RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L21 ANSWER 14 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:652131 ZCAPLUS

DOCUMENT NUMBER: 139:214237

TITLE: Preparation of nitrate prodrugs able to release nitric
 oxide in a controlled and selective way and their use
 for prevention and treatment of inflammatory, ischemic
 and proliferative diseases

INVENTOR(S): Scaramuzzino, Giovanni

PATENT ASSIGNEE(S): Italy

SOURCE: Eur. Pat. Appl., 313 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213
GI				



AB New pharmaceutical compds. of general formula F-(X)_q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ -tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO₂, nitrate salt, nitrite ester, ONO, thionitrite, SNO, etc., T = OR₁-M, OR₁OR₁-M, SR₁NR₂R₁-M, NR₂R₁-M, NR₂R₁SR₁-M, etc., R₁ = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R₂ = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R₁, R₂ = OH, SH, F, Cl, Br, OPO₃H₂, CO₂H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M₂, OZ-M₂, NR₂Z-M₂, R₁Z-M₂, OR₁Z-M₂, M₂ = M, R₁-M, OR₁-M, SR₁-M, NR₂R₁-M; ZM₂ = COCH₂CH(M₂)CH₂N+Me₃, COCH₂CH₂COM₂, COCH(NHR₂)CH₂M₂, etc.; Y = 4-COC₆H₄CH₂ONONO₂, O(CH₂)₄ONONO₂, COCH(NH₂)CH₂ONONO₂, 3-OC₆H₄CH₂ONONO₂, etc.] were prepared For example, α -tocopherol reacted with 4-HO₂CC₆H₄CH₂ONONO₂ to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586349-06-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)


RN 586349-06-6 ZCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, nitrate (1:?) (CA INDEX NAME)

CM 1

CRN 158876-82-5

CMF C26 H26 Cl N3



CM 2

CRN 7697-37-2

CMF H N O3



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 15 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:579665 ZCAPLUS

DOCUMENT NUMBER: 131:184874

TITLE: Preparation of
 8-chloro-6,11-dihydro-11[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine

INVENTOR(S): Carceller, Elena; Jimenez, Perez J.; Salas, Jordi

PATENT ASSIGNEE(S): J. Uriach & Cia. S. A., Spain


SOURCE: Span., 10 pp.
 CODEN: SPXXAD

DOCUMENT TYPE: Patent
 LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2120899	A1	19981101	ES 1996-2107	19961007
ES 2120899	B1	19990616		
PRIORITY APPLN. INFO.:			ES 1996-2107	19961007
GI				




AB UR-12592 (I) was prepared by coupling
 8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one with
 N-[(5-methyl-3-pyridinyl)methyl]-4-chloropiperidine and dehydrating with
 H₂SO₄.

IT 158876-82-5P, 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (UR-12592))

RN 158876-82-5 ZCAPLUS


CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-
 piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L21 ANSWER 16 OF 19 ZCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1997:30150 ZCAPLUS
 DOCUMENT NUMBER: 126:69591
 ORIGINAL REFERENCE NO.: 126:13317a,13320a
 TITLE: Rupatadine fumarate. UR-12592 fumarate. Antiallergic.
 Histamine and PAF antagonist

AUTHOR(S): Garcia-Rafanell, J.
 CORPORATE SOURCE: J. Uriach and Cia., Barcelona, 08026, Spain
 SOURCE: Drugs of the Future (1996), 21(10), 1032-1036
 CODEN: DRFUD4; ISSN: 0377-8282
 PUBLISHER: Prous
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 21 refs., describing the synthesis, pharmacol. actions, pharmacokinetics, toxicity, and clin. uses of the title drug.
 IT 158876-82-5P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation and pharmacol. of)
 RN 158876-82-5 ZCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,
 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 08:43:03 ON 13 APR 2011)

FILE 'REGISTRY' ENTERED AT 08:43:36 ON 13 APR 2011
 STRUCTURE UPLOADED

L1 1 S SAM SSS L1

FILE 'ZCAPLUS' ENTERED AT 08:45:51 ON 13 APR 2011
 S L1

FILE 'REGISTRY' ENTERED AT 08:46:00 ON 13 APR 2011
 L3 1 S L1 SSS SAM

FILE 'ZCAPLUS' ENTERED AT 08:46:00 ON 13 APR 2011
 L4 0 S L3 SSS SAM

FILE 'REGISTRY' ENTERED AT 08:46:10 ON 13 APR 2011

L5 1 S SAM SSS L1
 L6 STRUCTURE UPLOADED
 L7 0 S SAM SSS L6
 L8 31 S FULL SSS L6

FILE 'ZCAPLUS' ENTERED AT 08:51:03 ON 13 APR 2011
 L9 124 S L8

FILE 'REGISTRY' ENTERED AT 09:04:47 ON 13 APR 2011

FILE 'ZCAPLUS' ENTERED AT 09:06:02 ON 13 APR 2011
 L10 4 S L9 AND (CRYSTAL OR CRYSTALLINE)
 L11 1 S L9 AND POLYMORPH
 L12 5 S L9 AND POLYMORPH?
 L13 3 S L12 NOT L10
 L14 2 S L9 (L) POLYMORPH?
 L15 1 S L9 (W) POLYMORPH?
 L16 2 S L14 NOT L13
 L17 0 S L14 AND L13
 L18 0 S L14 NOT L10
 L19 21 S L8/PREP
 L20 19 S L19 NOT L10
 L21 19 S L20 NOT L13

=> exit

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
149.04	355.27

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-18.27	-18.27

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:27:45 ON 13 APR 2011